Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Notes Payables (2016 - 2019)

Historic Notes Payables for Arrowhead Pharmaceuticals (ARWR) over the last 8 years, with Q3 2019 value amounting to $2.7 million.

  • Arrowhead Pharmaceuticals' Notes Payables rose 110632.65% to $2.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $2.7 million, marking a year-over-year increase of 110632.65%. This contributed to the annual value of $2.7 million for FY2019, which is 110632.65% up from last year.
  • As of Q3 2019, Arrowhead Pharmaceuticals' Notes Payables stood at $2.7 million, which was up 110632.65% from $2.7 million recorded in Q2 2019.
  • Arrowhead Pharmaceuticals' 5-year Notes Payables high stood at $2.7 million for Q1 2019, and its period low was $144435.0 during Q2 2016.
  • Moreover, its 4-year median value for Notes Payables was $214130.0 (2017), whereas its average is $887358.9.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Notes Payables soared by 730.59% in 2017 and then skyrocketed by 114984.38% in 2019.
  • Arrowhead Pharmaceuticals' Notes Payables (Quarter) stood at $197713.0 in 2016, then grew by 7.34% to $212233.0 in 2017, then surged by 983.71% to $2.3 million in 2018, then grew by 17.39% to $2.7 million in 2019.
  • Its Notes Payables stands at $2.7 million for Q3 2019, versus $2.7 million for Q2 2019 and $2.7 million for Q1 2019.